Navigation Links
Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
Date:2/21/2008

OSLO, February 21 /PRNewswire-FirstCall/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, today announced that it will shortly commence clinical development of Alpharadin(TM) in HRPC patients in the USA. Algeta filed its Investigational New Drug (IND) application for its lead product Alpharadin(TM) with the United States Food and Drug Administration (FDA) in December 2007. The statutory 30 day consultation period was extended by the FDA for a further 30 days by agreement with the company and the IND has now been cleared by the FDA without any objections being made to the application. Alpharadin(TM) has already been studied in phase II clinical trials in Europe and has demonstrated a potential for a significant survival benefit in hormone-refractory prostate cancer (HRPC) patients with skeletal metastases.

An initial Phase I pharmacokinetics, biodistribution and dosimetry study (BC1-08) with Alpharadin in HRPC patients with skeletal metastases will be conducted at the Memorial Sloan-Kettering Cancer Center in New York, one of the world's leading oncology centers. This US trial will further expand the information obtained in a similar phase I study (BC1-05) conducted at the Royal Marsden Hospital in London, for which patient enrolment has recently been completed.

Following the start up of the BC1-08 trial, Algeta will continue discussions with the FDA to agree on the design of the further clinical development program for Alpharadin(TM)

"We are delighted to have been given the clearance by FDA to advance Alpharadin into clinical development in the United States, and to be working with one of the world's leading cancer centers on our clinical program," said Dr. Thomas Ramdahl, President and CEO of Algeta. "There is a great unmet medical need among men suffering from HRPC with skeletal metastases and the opening of this US clinical trial will be an important step in our overall clinical development of Alpharadin. As earlier announ
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... AZ (PRWEB) January 23, 2015 Hastings and ... injury matters, reports a record number of legal representation client ... speaking, there has been a steady rise in the number ... work and at home throughout the Valley. With that said, ... accident be reviewed by an experienced law firm. Hastings and ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ST. LOUIS, June 5 Celebrities, from high-profile,athletes to ... products,including expensive energy drinks and even candy bars, are ... it is the nutrient fad of the,moment., Fleming ... on the market ranged from 40% all the way ...
... Diana Kirschner Explains the Psychology Behind It, NEW ... an estimated,$55.7 million for its opening weekend, beating out ... other romantic comedy has ever,opened with such a lucrative ... occurring," says Dr. Diana Kirschner, psychologist and,recurring relationship expert ...
... Expects FDA to Request Additional Safety Study Prior to ... Inc.,(Nasdaq: IDEV ) today announced that based on ... (FDA) regarding the NDA filing for,NEBIDO(R), the Company expects ... safety data prior to approving NEBIDO. The Company,currently believes ...
... risk of developing rheumatoid arthritis by up to 50%, ... of the Rheumatic Diseases. , The Scandinavian researchers base ... in two separate studies, which assessed environmental and genetic ... the participants (1650) had the disease and had been ...
... FALLS CHURCH, Va., June 4 CSC (NYSE: ... Dell Inc. (Nasdaq: DELL ) to design and,deploy ... and,complexity out of their information technology (IT) environment and ... help clients,simplify processes associated with IT and enhance innovation ...
... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
Cached Medicine News:Health News:The Vitamin B12 Craze - Super Nutrient or Super Hype? 2Health News:Why is the Sex & the City Movie a Mega-Blockbuster? 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 3Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 4Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 5Health News:Regular tipple may curb risk of rheumatoid arthritis 2Health News:CSC to Simplify IT From Desktop to Data Center 2Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Bayer HealthCare LLC announced today that it has ... and Farnam Companies Inc. over Farnam,s advertising for its ... of the settlement, Farnam has agreed to withdraw the ... campaign included claims that Bio Spot® was "as effective ...
... CLARA, Calif., June 17, 2011 NewCardio, Inc., (OTC ... that Vincent Renz, Chief Executive Officer, is scheduled to ... Conference is on June 22 and 23, 2011, at ... 3:30 p.m. ET on Wednesday, June 22. ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 3
... The Optimal temporary implant for use with ... The pupil dilator type 5S is a ... of the pupil during phacoemulsification. It is ... use. Indication: Expansion of the pupil during ...
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
For use with Crawford Intubation Systems....
... prolene as thread-guide reducing time and trauma ... Probe is inserted into the nasolacrimal duct ... through it. The probe is then withdrawn ... silicone tubing in place. Canalicular Laceration or ...
Medicine Products: